Fin Cascade
Get Android appGet iOS app

Prices as of 8 Oct 2026 close · Not investment advice

Pfizer Limited

NSE: PFIZERPharmaceuticals

Share price

₹3,750.00

-1.71% close of 8 Oct 2026

Market cap ₹17,250 CrP/E 23.5

Price-based ratios (P/B, dividend yield, EV/EBITDA) are as of 6 Oct 2026, the close above is 8 Oct 2026.

Business score

How strong the business is, in one number. The parts behind it are in Pro.

65

out of 100 · worked out 8 Oct 2026

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹17,250 Cr

P/E ratio

23.5

P/B ratio

4.1

ROCE

24.1%

ROE

3.6%

Dividend yield

1.9%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 8 Oct 2026 close52-week high ₹5,529.5052-week low ₹3,750.00

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Sales grew 10.7% over the past year, and 8.0% a year over its longer record. Meanwhile what it keeps of every 100 rupees of sales improved from 30.3% to 36.6% over the last four years.

Whether it grew faster than its sector

It grew 8.0% a year against a sector median of 13.1% — 5.1 percentage points slower.

Room to re-rate, or risk of de-rating

At 23.5× earnings against a market that pays 23.9× across 2199 companies we can price. Its own industry sits at 78.7×, across 5 companies. It is against its own five-year median of 32.4×, the 0th percentile of its own range.

Whether growth justifies the valuation

Priced at 2.9 times its growth rate, on earnings growth of 8%.

Profit growthPrice per ₹1 profitPer 1% growth
Pfizer Limited — this one8%/yr23.5×₹2.9
Sun Pharmaceutical13%/yr33.4×₹2.6
Divi's Laboratories13%/yr83.3×₹6.4
Torrent Pharmaceuticals22%/yr78.7×₹3.6
Zydus Lifesciences32%/yr23.1×₹0.72
Laurus Labs Limited4%/yr98.6×₹24.7

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies the exchange files under the same label (Pharmaceuticals), it ranks 27 of 130 on returns, 87 of 127 on growth, 8 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

A wide advantage: it earns 24.1% on capital, ahead of 79% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Whether its growth pays for itself

Yes — Over the last five years it made ₹2908 crore of cash from the business, spent ₹56 crore on plant and equipment, and returned ₹1765 crore to lenders and shareholders. And the profit is real: of every 100 rupees it reported over 12 years, about 84 arrived as cash. Its cash comes back more slowly than it used to: it went from being paid 14 days before it paid its own suppliers to waiting 9 days for its cash.

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

8 of 9 checks clear · 89%

Latest result · Q1 FY27

What the last results showed. Whether management kept its word is in Pro.

Sales rose 8% to Rs 653 crore and profit 7% to Rs 204 crore

Announced 28 Jul 2026 · Standalone

Revenue

₹653 Cr

Net profit

₹204 Cr

Net margin

31.3%

EPS

₹44.69

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap
₹17,250 Cr
Prev close
₹3,750.00
52w High
₹5,579
52w Low
₹3,731
Enterprise value
₹14,209 Cr
Beta
0.5
Price CAGR 1y
-26.0%
Price CAGR 3y
-1.0%
Price CAGR 5y
-7.0%
Price CAGR 10y
7.0%

Ratios

Return on assets
14.7%
PEG ratio
2.8
P/E ratio
23.5
P/B ratio
4.1
EV / EBITDA
15.1
Industry P/E
38.0
ROCE
24.1%
ROCE 5y average
24.4%
ROE
3.6%
Debt / Equity
0.0
Interest coverage
98.6
Dividend yield
1.9%
ROE 3y average
16.0%
ROE last year
18.0%

Annual P&L

Annual revenue
₹2,520 Cr
Annual profit
₹722 Cr
Operating margin
36.0%
Net profit margin
28.7%
EBITDA margin
35.9%
Sales growth 3y
1.3%
Sales growth 5y
2.4%
Profit growth 3y
8.0%
Profit growth 5y
9.0%
EPS
₹158
Sales growth TTM
11.0%
Profit growth TTM
14.0%
Dividend payout
48.0%

Quarter P&L

Sales latest quarter
₹653 Cr
Profit latest quarter
₹204 Cr
YoY quarterly sales growth
8.3%
YoY quarterly profit growth
6.3%
OPM latest quarter
37.9%

Balance Sheet

Book Value
₹914
Face Value
₹10.0
Total debt
₹70 Cr
Total cash
₹3,111 Cr
Borrowings
₹70 Cr
Reserves / Equity
90.4

Cash Flow

Operating cash flow
₹968 Cr
Free cash flow
₹944 Cr
FCF yield
5.4%
Net cash flow
-₹392 Cr

Shareholding

Promoter holding
63.9%
FII holding
1.6%
DII holding
17.8%
Public holding
16.6%

Peer comparison

CompanyPrice ₹P/EMkt cap ₹ CrDiv yield %Profit qtr ₹ CrProfit var %Sales qtr ₹ CrSales var %ROCE %
Sun Pharma.Inds.1,804.1034.24,32,3050.892,901.26.015,299.910.520.5
Divi's Lab.9,550.0085.12,53,5220.31902.065.53,080.027.822.0
Torrent Pharma.4,772.0081.61,82,1550.80566.05.84,921.054.915.2
Zydus Lifesci.1,159.5023.81,15,6610.09990.2-35.18,017.022.021.1
Laurus Labs2,050.00101.71,11,1810.10362.1125.52,026.329.117.8
Cipla1,340.2030.31,08,2710.97785.6-39.27,119.32.315.5
Mankind Pharma2,500.0048.41,03,2220.04574.129.64,030.612.913.5
Pfizer3,852.2022.917,6331.95204.56.6653.28.324.1
Median427.8034.62,2190.0813.529.5164.018.415.0

Competes with: Aurobindo Pharma, Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Lupin, Mankind Pharma Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Standalone · to 30 Jun 2026
Line itemJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales531575540547563589538592603642645629653
Expenses421393387357385399392364393412417393406
Material Cost7189706883105
Change in Inventories-7.68-1.74-631220-48
Purchases of Stock-in-Trade140124221145118183
Employee Cost8396951007782
Other Expenses798690929683
Operating Profit111183153189177189146228210230228236248
OPM %21322835323227383536353838
Other Income333644754243432176742-205045
Exceptional items (within Other Income)17300-589.040
Interest3337222332221
Depreciation16151814151515161414141514
Profit before tax126201176244203215172426260255192269277
Tax %26262627262626222626262626
Net Profit94149130179151158128331192189142200204
EPS in Rs20332839333528724241314445
Diluted EPS in Rs72420314445

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Standalone · to 31 Mar 2026
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales1,8532,0121,9661,9692,0822,1522,2392,6112,4252,1932,2812,5202,570
Expenses1,4381,5791,6161,4681,5161,5781,5261,7751,6161,5551,5401,6151,628
Material Cost272310
Change in Inventories25-34
Purchases of Stock-in-Trade513608
Employee Cost371368
Other Expenses359363
Operating Profit414433350501566574712836809638742904942
OPM %22221825272732323329333637
Other Income44972321141671838163134185344139116
Exceptional items (within Other Income)173-49
Interest2121211151113158108
Depreciation2505863667110310911510662615858
Profit before tax2074705175486606426697738247461,016976993
Tax %663535343521262124262426
Net Profit70305337360429509498613624551768722735
EPS in Rs1567747994111109134136121168158161
Diluted EPS in Rs168158
Dividend Payout %8222272524297322629299848

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years
2%
5 years
2%
3 years
1%
TTM
11%

Compounded profit growth

10 years
10%
5 years
9%
3 years
8%
TTM
14%

Stock price CAGR

10 years
7%
5 years
-7%
3 years
-1%
1 year
-26%

Return on equity

10 years
17%
5 years
18%
3 years
16%
Last year
18%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Standalone
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital464646464646464646464646
Reserves1,9272,1182,3732,6372,9663,3502,3472,8193,1623,5504,1724,157
Borrowings2222226339414010870
Other Liabilities6387228401,0049261,007810997752593585649
Total Liabilities2,6142,8883,2613,6903,9404,4053,2663,9014,0014,2294,9114,922
Fixed Assets944925902950886973894869749713724678
CWIP133151-013180820
Investments4337-0-0-0-0-0-0-0-0-0-0
Other Assets1,6141,9232,3432,7393,0543,4322,3693,0303,2443,5164,1804,224
Total Assets2,6142,8883,2613,6903,9404,4053,2663,9014,0014,2294,9114,922

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Standalone
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity11334532933298323427667356257660968
Cash from Investing Activity68-701-250-238351,530-469-575-3654-71-562
Cash from Financing Activity-1-62-83-110-110-164-1,571-181-346-235-205-798
Net Cash Flow181-417-3-17231,690-1,613-88-2675383-392
Free Cash Flow93398394262125343410654292291783944

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Standalone
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days322620293029182023313126
Inventory Days191167148147189198199173175200214195
Days Payable16515717824521319713010291776889
Cash Conversion Cycle5836-10-696318791107154177132
Working Capital Days7-9-47-57-16-83-14124239
ROCE %242217212320232926222124

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Standalone · to 30 Jun 2026
Line itemSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters646464646464646464646464
FIIs2.823.033.323.223.542.742.182.402.602.712.811.65
DIIs151515161617171717171718
Public181817171717171616161617
No. of Shareholders1,16,9481,12,4561,09,2141,06,09898,8241,05,0151,08,2611,03,2221,03,4801,00,93399,5451,02,478

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year -28.8% (₹5,266.50 → ₹3,750.00)Brick size ₹85.53 (fixed)Bricks 56
₹4,000₹4,500₹5,000₹5,500₹3,750Nov '25Feb '26Apr '26Jun '26Aug '26Oct '26
Price moved up one brickPrice moved down one brickLast close ₹3,750.00 on 8 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

1 when an audit qualification is filed as repetitive

0.00flag

2026-03-31

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

0.00cr

2026-06-30

net debt from the filed balance sheet at the newest year end: Borrowings − Cash Equivalents − Investments (Current); negative = net cash

-3,041inr_cr

2026-03-31

guarantees / comfort given for promoter, promoter group, directors and KMP

0.00cr

2026-03-31

loans outstanding to promoter, promoter group, directors and KMP (governance filing)

0.00cr

2026-03-31

security given for the borrowing of promoter, promoter group, directors and KMP

0.00cr

2026-03-31

FY revenue / permanent employees + workers, same basis (calc)

2,02,57,235inr

2026-03-31

News

News and filings about Pfizer Limited. Open one to see why it matters.

29 Sept, 13:30 IST · Company event · low impact

Pfizer Limited — Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Company has, on September 28, 2026, received an Order dated September 25, 2026, issued by the Deputy / Additional Commissioner of Income tax Transfer Pricing, levying a penalty of Rs. 1,26,34,050/- based on the Transfer Pricing audit conducted for the Assessment Year 2023-24.

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

Competes with

Uses as raw material

  • Active pharmaceutical ingredients (APIs) and bulk drugs
  • Packaging materials

Buys drug ingredients from

  • Pfizer Service Company BVBA, Belgium

Buys from

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector
Healthcare
Industry
Pharmaceuticals
Classification
Healthcare › Pharmaceuticals
ISIN
INE182A01018

Plants

  • Pfizer Limited Goa manufacturing facility · Verna / Salcete, Goa

News impact

Big market events that reach Pfizer Limited, and how the effect spreads.

Who it hits first

  • AbbVie (ABBV) and Apogee Therapeutics are US-listed; neither is in the Indian knowledge graph — zero direct impact on Indian listed companies.

Who may gain

  • Sentiment-level read-across to Indian biologics/biosimilar innovators (immunology-biologics theme stays in focus) and, as a diffuse long-term theme, the CDMO/CRO category as global pharma deploys M&A capital.

Along the supply chain

Downstream

No downstream supply-chain link — a US biotech acquisition does not change product flows to or from any Indian listed company.

Upstream

No upstream supply-chain link — AbbVie and Apogee are US entities; no Indian listed company supplies APIs, intermediates or services into this specific transaction.

Where demand moves

Business

No direct business-demand flow — the AbbVie-Apogee deal neither creates nor destroys orders for any Indian company. Any effect (global pharma capital deployment lifting long-term outsourcing demand for Indian CDMO/CRO players) is a diffuse second-order theme, not a measurable order shift.

Capital

Capital-flow read-across only — a global immunology M&A reinforces a positive innovator-pharma narrative that can support Indian pharma valuations at the margin; the effect is sentiment-level and strongest for biologics/biosimilar names such as Biocon.

How it spreads across sectors

Healthcare

negligible — hospital operators have no business channel to a US drug-developer acquisition

Pharma

mild positive sentiment from the global pharma M&A consolidation/innovation theme

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Dividends

17 Jul 2026unspecified₹75
9 Jul 2025unspecified₹35
9 Jul 2025special₹100
9 Jul 2025special₹30
21 Aug 2024unspecified₹35
11 Aug 2023unspecified₹35
11 Aug 2023special₹5
19 Sep 2022special₹30

Splits, bonuses & buybacks

  • daily-prices repair: 9 rows from NSE's archive (replace 1, delete 1, insert 7), 2016-10-30..2026-02-01 (docs/flat_day_repair.md)1× · 30 Oct 2016

Documents

Annual reports, results presentations and earnings calls, straight from the source.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.